MDSpire - Summary
Conference News

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...

Share

The treatment landscape for myelofibrosis is shifting as new therapies, notably combinations with JAK inhibitors and novel agents, show promising results. Major findings presented at the 2025 ASH Annual Meeting highlight the efficacy of pelabresib plus ruxolitinib in JAK inhibitor-naive patients, demonstrating significant improvements in spleen volume and safety profiles. Other studies, including elritercept's results paired with ruxolitinib for patients with anemia, indicate robust efficacy. Meanwhile, stem cell transplantation remains a curative option for high-risk patients, reinforcing the importance of precise management strategies for optimization.

Original Source(s)

ASH 2025: Myelofibrosis Roundup

  • by Caroline Helwick

  • March 24, 2026

Related Content

Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precurso...

POEMS Syndrome: Diagnostic Clues From Neuropathy to Bone Marrow Findings

POEMS syndrome is a poorly understood and complex paraneoplastic plasma cell disorder characterized by peripheral neuropathy and multisystem involvement, including organomegaly, endocrinopathy, monocl...

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...